Olaparib monohydrate

Olaparib monohydrate is a PARP inhibitor used to treat cancers with BRCA mutations, including ovarian, breast, pancreatic, and prostate cancers. It works by blocking DNA repair in cancer cells, leading to cell death. Used as both treatment and maintenance therapy after chemotherapy. It is grouped under the following drug class(es): Antineoplastic agents and PARP Inhibitors. Its therapeutic use is listed as antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Olaparib hydrate and Lynparza. Its PubChem CID is 168798820.

CAS No 2093369-28-7
Molecular Formula C24H25FN4O4
Molecular Weight 452.5 g/mol
Synonyms 4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one;hydrate

Frequently Asked Questions